Schedule a no-obligation demo to see for yourself how MicroPulse Technology and IRIDEX’s Family of Products can take YOUR practice to the next level.
A long-term retrospective review of 274 consecutive eyes with macular edema due to DME or BRVO that were treated with MicroPulse high density laser treatment using various duty cycles and followed for up to 10 years. Authors’ conclusions: High density MicroPulse laser treatment effectively treats retinovascular macular edema without laser-induced retinal damage
A prospective, double-masked, controlled clinical trial on 123 eyes with DME. Three dosing protocols were compared and patients were followed for a minimum of 1 year. Authors’ conclusions: High density MicroPulse treatment is superior to the mETDRS based on BCVA improvement and CMT reduction.
A prospective, randomized clinical trial on 62 eyes (50 patients) with untreated, center-involving, clinically significant DME, treated with either ETDRS or subthreshold MicroPulse laser therapy. Authors’ conclusions: High density MicroPulse laser is as effective as mETDRS laser in stabilizing visual acuity and in reducing macular edema with the benefits of no tissue damage detectable at any time point postoperatively, and of significant improvement in retinal sensitivity.
A comparative, controlled, prospective study comparing MicroPulse, intravitreal BCZ injection, and observation for the treatment of CSC in 52 eyes of 52 patients. Authors’ conclusions: Results indicate superior subretinal fluid resolution, and superior VA improvement and other visual functions, for MicroPulse laser compared to anti-VEGF injections, with no tissue reactions observed during and at any point after MicroPulse treatment.
A review of the role and evolution of retinal laser treatment for DME, including the state-of-the-art of clinically effective and harmless subthreshold diode (810 nm) laser MicroPulse photocoagulation for the treatment of DME. Authors’ summary: The discovery of clinically effective and harmless SDM treatment for DME offers exciting new information that will improve our understanding of laser treatment for retinal disease, expand treatment indications, and improve patient outcomes.
A prospective study of 24 eyes, with CSC for more than 3 months with no prior intervention, were treated with nonvisible MicroPulse laser. Mean follow-up was 14 months (mean, range 3 to 36 months). Authors’ conclusions: The majority of eyes achieved anatomic and functional improvements. MicroPulse is a new and promising method for treating a previously untreatable disorder. This minimally invasive and retina sparing treatment may allow the cure of CSC at its earlier stages when irreversible visual loss has not occurred
A retrospective case series of 5 patients with CSC treated with MicroPulse. At 17.1 months (mean, range 6 to 24 months) follow-up, 4 of 5 patients had complete resolution of symptoms. Authors’ conclusions: Outcomes confirm long-term efficacy of MicroPulse in the management of CSC. It produces therapeutic effects that appear comparable to those of conventional PC with no detectable signs of laser-induced iatrogenic damage
Multiple articles addressing physicians’ clinical experience using tissue-sparing MicroPulse laser to treat DME and macular edema secondary to BRVO.
Lasers Delivery Devices Retina Consumables Glaucoma Device
Physician Information Patient Information Clinical Library
Overview News Events Contact Us
Investors Offices/Contact Careers